Mosanna Therapeutics gains $80m to advance OSA nasal spray
The new funding will support MOS118 through its Phase II development while expanding Mosanna's product pipeline.
Therapy Area
RFK Jr axes vaccine advisory committee members
MSD receives FDA approval for Enflonsia to prevent RSV
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
Aytu BioPharma to commercialise Exxua for MDD in the US
EC approves AstraZeneca’s acalabrutinib combo for CLL
ADHD drugs back in the spotlight after study debunks rising prevalence
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
